- Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
May 6, 2026 · globenewswire.com
Conference Call and Webcast Scheduled for May 13, 2026 at 2 p.m. PT/5 p.m. ET SOUTH SAN FRANCISCO, Calif.
- ALLOGENE THERAPEUTICS TO REPORT FIRST QUARTER FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE
May 6, 2026
CONFERENCE CALL AND WEBCAST SCHEDULED FOR MAY 13, 2026 AT 2 P.M. PT/5 P.M. ET SOUTH SAN FRANCISCO, CALIF.
- William Blair Initiates Natera (NTRA) With Outperform
May 2, 2026
Natera, Inc. (NASDAQ:NTRA) is one of the Stocks that Billionaire Druckenmiller and Jim Cramer like.William Blair Initiates Natera (NTRA) With Outperform
William Blair initiated coverage of Natera, Inc. (NASDAQ:NTRA) with an Outperform rating on the company’s stock on April 14, 2026. The firm recommends the stock as a core, long-term growth holding. William Blair highlights Natera, Inc. (NASDAQ:NTRA)’s leadership in major diagnostic markets and its diversified, expanding portfolio, positioning the company as a top investment choice in the medical technology sector.
Separately, on April 13, 2026, Natera, Inc. (NASDAQ:NTRA) highlighted positive interim results from Allogene Therapeutics’ (ALLO) registrational ALPHA3 trial, which uses the company’s CLARITY MRD assay. The study evaluates cema-cel CAR T therapy in patients with large B-cell lymphoma who remain positive for molecular residual disease (MRD) after initial treatment. Analysis showed 58.3% of MRD-positive patients achieved clearance with cema-cel. Median plasma ctDNA levels went down 97.7% in the treatment arm, compared to a 26.6% increase in the observation group. These findings offer early evidence of drug performance and reflect Natera, Inc. (NASDAQ:NTRA)’s phased variant technology in identifying high-risk patients.
Notably, the fourth quarter of 2025 established the stock as the largest holding at 12.8% of Druckenmiller’s portfolio. While acknowledging its growth in diagnostic testing, Jim Cramer takes a cautious view of the company.
Founded in 2003, Natera, Inc. (NASDAQ:NTRA) is a leader in cell-free DNA (cfDNA) and genetic testing. The Texas-based company specializes in high-sensitivity molecular diagnostics across three primary domains: women’s health (NIPT), oncology (MRD), and organ health (transplant rejection).
While we acknowledge the potential of NTRA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 New Contenders for S&P 500 Indexand Harvard University Stock Portfolio: Top 10 Stock Picks.
Disclosure: None. Follow Insider Monkey on Google News.
View Comments
- Allogene Therapeutics (ALLO) Closes $200.4M Public Offering of Common Stock
May 1, 2026
Allogene Therapeutics Inc. (NASDAQ:ALLO) is one of the best biotech penny stocks to buy in 2026. On April 16, Allogene Therapeutics closed its underwritten public offering, raising $200.4 million in aggregate gross proceeds. The offering consisted of 87.5 million shares of common stock priced at $2.00 per share, plus an additional 12.7 million shares purchased through a partial exercise of the underwriters’ option. The transaction involved a large syndicate of financial institutions, with Goldman Sachs & Co. LLC, Jefferies, and TD Cowen serving as lead joint bookrunners.
The company intends to use the net proceeds for general corporate purposes. Key areas of allocation include clinical trial expenses, ongoing R&D, G&A costs, and capital expenditures. This capital infusion provides Allogene Therapeutics Inc. (NASDAQ:ALLO) with enhanced financial flexibility to advance its pipeline of off-the-shelf chimeric antigen receptor T-cell (CAR T) therapies.
The offering was executed under an existing shelf registration statement that became effective in April 2024. Following the closing, the company’s common stock was trading down approximately 2.67%. Joint bookrunners for the deal also included Piper Sandler and William Blair, while Baird, Canaccord Genuity, and TPG Capital BD, LLC provided additional management and co-management support.Allogene Therapeutics (ALLO) Closes $200.4M Public Offering of Common Stock
Allogene Therapeutics Inc. (NASDAQ:ALLO) is a clinical-stage biotechnology company dedicated to the development of off-the-shelf allogeneic CAR-T cell therapies for cancer and autoimmune diseases. The company’s goal is to provide a scalable, readily available cell therapy derived from healthy donors.
While we acknowledge the potential of ALLO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
View Comments
- Allogene Therapeutics (ALLO): 10 Best Growth Stocks Under $10 to Invest In
Apr 25, 2026
Allogene Therapeutics Inc. (NASDAQ:ALLO) is one of the best growth stocks under $10 to invest in. On April 21, Allogene Therapeutics received regulatory clearance to expand its pivotal Phase 2 ALPHA3 study of cemacabtagene ansegedleucel (cema-cel) into South Korea and Australia. This expansion increases the trial’s global footprint to over 80 sites, up from the current 60 in North America, with patient screening and enrollment in these new regions expected to begin in Q2 2026.
The study evaluates cema-cel as a first-line consolidation treatment for patients with large B-cell lymphoma/LBCL who show minimal residual disease/MRD after initial chemotherapy. The decision to expand follows positive interim futility analysis data from the first 24 patients, which showed that cema-cel achieved a 58.3% MRD clearance rate compared to just 16.7% in the standard-of-care observation group. Additionally, the therapy was well-tolerated with no reported cases of cytokine release syndrome or neurotoxicity.Allogene Therapeutics (ALLO): 10 Best Growth Stocks Under $10 to Invest In
Allogene Therapeutics Inc. (NASDAQ:ALLO) aims to enroll ~220 patients in the ALPHA3 trial by the end of 2027. An interim analysis of event-free survival is planned for mid-2027, with the primary analysis following in mid-2028 to potentially support a BLA submission. Cema-cel, which has already received the RMAT designation from the FDA, represents a next-generation off-the-shelf AlloCAR T product designed to address the 30% of LBCL patients who typically relapse under the current watch-and-wait standard of care.
Allogene Therapeutics Inc. (NASDAQ:ALLO) is a clinical-stage biotechnology company dedicated to the development of off-the-shelf allogeneic CAR-T cell therapies for cancer and autoimmune diseases. The company’s goal is to provide a scalable, readily available cell therapy derived from healthy donors.
While we acknowledge the potential of ALLO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
View Comments
- H.C. Wainwright Maintains Buy Rating on Allogene Therapeutics (ALLO)
Apr 23, 2026
Allogene Therapeutics, Inc. (NASDAQ:ALLO) is one of the
10 Best Penny Stocks to Buy and Hold Under $5.
On April 15, 2026, H.C. Wainwright lowered its price target on Allogene Therapeutics, Inc. (NASDAQ:ALLO) to $11 from $12 while maintaining a Buy rating following the pricing of its previously announced $175M common stock offering. The firm said the recent share pullback appears “unwarranted” and views it as an attractive entry point.
Meanwhile, Jefferies analyst Roger Song raised his price target to $10 from $6 and kept a Buy rating after interim data from the Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma exceeded expectations. The firm sees meaningful upside potential based on the early results.
On April 12, 2026, Allogene reported data from a planned interim futility analysis of the ALPHA3 trial. At the protocol-defined cutoff—triggered when the 24th patient completed a Day 45 MRD assessment—58.3% of patients treated with cema-cel achieved minimal residual disease (MRD) negativity versus 16.7% in the observation arm, a 41.6 percentage point difference. Prior literature suggests that a 25%–30% MRD clearance gap could translate into meaningful clinical benefit. Plasma ctDNA levels declined by a median of 97.7% from baseline in the cema-cel arm, compared to a 26.6% increase in the observation group.H.C. Wainwright Maintains Buy Rating on Allogene Therapeutics (ALLO)
Photo by National Cancer Institute on Unsplash
The therapy was generally well tolerated, with no serious treatment-related adverse events reported and no cases of cytokine release syndrome, neurotoxicity, or graft-versus-host disease. Ten of 12 patients in the treatment arm were managed entirely in outpatient settings, contrasting with broader CAR-T experiences where hospitalization rates typically range from 70% to 90%. Although based on a small sample size, baseline characteristics indicated that the cema-cel arm included a higher proportion of patients with more aggressive disease features.
Allogene Therapeutics, Inc. (NASDAQ:ALLO) develops allogeneic CAR-T cell therapies for cancer and autoimmune diseases.
While we acknowledge the potential of ALLO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
View Comments
- Wave Life Sciences Ltd. (WVE) Sees Strong Buy Rating From Analysts
Apr 22, 2026
Wave Life Sciences Ltd. (NASDAQ:WVE) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The company’s stock registered a 22.39% growth from a year ago and a 53.04% percent decline year-to-date. Based on analyst consensus, Wave Life Sciences continues to see a Strong Buy Rating from Wall Street analysts with an average price target of $26.15.Why Allogene Therapeutics (ALLO) Says Its Lead Cancer Program Is Still on Track in 2026
On April 15, Wave Life Sciences announced that its board of directors unanimously approved a plan to redomicile the parent company of the Wave Life Sciences group of companies from Singapore to the United States. It emphasized that having Wave’s parent company domiciled in the United States will streamline Wave’s organizational, statutory, and regulatory structure, resulting in administrative efficiencies and reducing dual financial reporting, regulatory, legal, and other compliance costs, among other benefits.
Through Wave Life Sciences’ listing on NASDAQ, the company has already built a substantial presence in the U.S., with the majority of its operations, its corporate headquarters, the majority of its operating assets, including its manufacturing and research and development facilities, along with the majority of its employees, management team, and board of directors being in the United States.
Wave Life Sciences Chief Financial Officer Kyle Moran said the company believes the United States is the best place to enhance shareholder value. He added:
“With several of our investigational therapies showing tremendous potential to become first- and/or best-in-class treatments, now is the right time and becoming a Delaware corporation is the right strategic move for Wave in order to better align our parent company’s domicile with our operations and our people.”
Wave Life Sciences Ltd. (NASDAQ:WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and common disorders.
While we acknowledge the potential of WVE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Best Data Center Stocks to Buy for the Long Term and 8 Must-Buy Small Cap Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
View Comments
- Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
Apr 21, 2026 · globenewswire.com
SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that regulatory authorities in South Korea and Australia have cleared the Company to expand its pivotal Phase 2 ALPHA3 study evaluating cemacabtagene ansegedleucel (cema-cel) in first-line (1L) consolidation treatment for patients with large B-cell lymphoma (LBCL).
- ALLOGENE THERAPEUTICS EXPANDS PIVOTAL PHASE 2 ALPHA3 TRIAL TO SOUTH KOREA AND AUSTRALIA
Apr 21, 2026
SOUTH SAN FRANCISCO, CALIF., APRIL 21, 2026 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ: ALLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF ALLOGENEIC CAR T (ALLOCAR T) PRODUCTS FOR CANCER AND AUTOIMMUNE DISEASE, TODAY ANNOUNCED THAT REGULATORY AUTHORITIES IN SOUTH KOREA AND AUSTRALIA HAVE CLEARED THE COMPANY TO EXPAND ITS PIVOTAL PHASE 2 ALPHA3 STUDY EVALUATING CEMACABTAGENE ANSEGEDLEUCEL (CEMA-CEL) IN FIRST-LINE (1L) CONSOLIDATION TREATMENT FOR PATIENTS WITH LARGE B-CELL LYMPHOMA (LBCL).
- Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
Apr 20, 2026 · globenewswire.com
SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products, today announced upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, April 17-22, 2026, in San Diego, Calif.
